Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET

Molecular Oncology
Elena Hernández-AgudoMiguel Quintela-Fandino

Abstract

Rationalization of antiangiogenics requires biomarkers. Vascular re-normalization is one widely accepted mechanism of action for this drug class. The interstitium of tumors with abnormal vasculature is hypoxic. We sought to track vascular normalization with (18)F-misonidazole ([18F]-FMISO, a probe that detects hypoxia) PET, in response to window-of-opportunity (WoO) treatment with the antiangiogenic dovitinib. Two patient-derived pancreas xenografts (PDXs; Panc215 and Panc286) and the spontaneous breast cancer model MMTV-PyMT were used. Animals were treated during 1 week of WoO treatment with vehicle or dovitinib, preceded and followed by [18F]-FMISO-PET, [18F]-FDG-PET, and histologic assessment (dextran extravasation, hypoxia and microvessel staining, and necrosis, cleaved caspase-3 and Ki67 measurements). After WoO treatment, gemcitabine (pancreas)/adriamycin (breast) or vehicle was added and animals were treated until the humane endpoint. Tumor growth inhibition (TGI) and survival were the parameters studied. [18F]-FMISO SUV did not change after dovitinib-WoO treatment compared to vehicle-WoO (0.54 vs. 0.6) treatment in Panc215, but it decreased significantly in Panc286 (0.58 vs. 1.18; P < 0.05). In parallel, 10-KDa perivasc...Continue Reading

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Jun 20, 2002·Journal of the National Cancer Institute·Lynn HlatkyJudah Folkman
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sang Hoon LeeCarla Heise
Aug 11, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Belen Rubio-ViqueiraManuel Hidalgo
Aug 18, 2006·Nature Reviews. Drug Discovery·Norman E Sharpless, Ronald A Depinho
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jun 5, 2007·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Susanne Martina EschmannRoland Bares
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Jan 25, 2011·Nature Reviews. Cancer·Giulio FranciaRobert S Kerbel
Nov 2, 2011·The Breast : Official Journal of the European Society of Mastology·Robert S Kerbel
Dec 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jingli WangWilliam R Wilson
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators
Jan 11, 2012·Oncology·Toshiharu Sakurai, Masatoshi Kudo
Feb 22, 2012·Expert Opinion on Investigational Drugs·Marco PetrilloGabriella Ferrandina
May 4, 2012·Cold Spring Harbor Perspectives in Medicine·Patrick R Lawler, Jack Lawler
May 17, 2012·Clinical Pharmacology and Therapeutics·G Z Ferl, R E Port
Sep 27, 2012·Journal of Mammary Gland Biology and Neoplasia·Robert S Kerbel
May 15, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rakesh K Jain
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Robert S KerbelShan Man
Dec 24, 2013·Cancer Treatment Reviews·Gabriel Limaverde-SousaCarlos Gil Ferreira
May 16, 2014·Nature Reviews. Cancer·Daniele M GilkesDenis Wirtz
Jul 16, 2014·Seminars in Oncology·MengJie YanPaul Jurasz

❮ Previous
Next ❯

Citations

Mar 17, 2017·British Journal of Cancer·Maria J BuenoMiguel Quintela-Fandino
Sep 19, 2017·Expert Opinion on Therapeutic Targets·Javier A Menendez, Ruth Lupu
Jun 22, 2019·PLoS Computational Biology·Paul W SweeneyRebecca J Shipley
Nov 9, 2016·International Journal of Oncology·Ewa MajJoanna Wietrzyk
Jan 24, 2017·Frontiers in Pharmacology·Gabriella LupoCarmelina D Anfuso
Nov 20, 2016·Molecular & Cellular Oncology·M Quintela-Fandino
Nov 14, 2018·Contrast Media & Molecular Imaging·Sven De BruyckerSigrid Stroobants
Mar 14, 2020·Nature Biomedical Engineering·Katja HaedickeJan Grimm
Sep 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel Quintela-FandinoRamon Colomer
Oct 11, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel Quintela-FandinoSilvana Mouron
May 18, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth R GerstnerUNKNOWN ACRIN 6684 Trial Group
Sep 3, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Renata Salgado FernandesAndré Luís Branco de Barros
Dec 12, 2020·Acta Pharmaceutica Sinica. B·Yang ZhaoJia Li
Apr 1, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Milan GrkovskiSean D Carlin
Jul 1, 2021·Cell Biology International·Keywan Mortezaee
Sep 4, 2021·Frontiers in Oncology·Ting YangXinggang Guo

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
confocal microscopy
imaging techniques

Software Mentioned

Ariol
Definiens Developer XD
SPSS Statistics

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.